Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-20-001879
Filing Date
2020-01-17
Accepted
2020-01-17 09:05:42
Documents
2
Period of Report
2020-01-08

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 15613
2 POWER OF ATTORNEY (PUBLIC): EXHIBIT 24 - POWER OF ATTORNEY doc1.txt EX-24 3682
  Complete submission text file 0001127602-20-001879.txt   20687
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703
Business Address
Jones Michael L (Reporting) CIK: 0001800060 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-23186 | Film No.: 20532379